Intra-Cellular Therapies, Inc. (23I.F)

60,00 0,00 (0,00%) Börsenschluss: 08:38AM CEST

Intra-Cellular Therapies, Inc.

430 East 29th Street
New York, NY 10016
United States
646 440 9333
https://www.intracellulartherapies.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 610

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Sharon Mates Ph.D.	Co-Founder, Chairman & CEO	2,15M	1,99M	1953
Mr. Michael I. Halstead J.D.	President	944,97k	1,86M	1973
Dr. Suresh K. Durgam M.D.	Executive VP & Chief Medical Officer	931,1k	N/A	1969
Mr. Mark Neumann	EVP & Chief Commercial Officer	960,43k	2,84M	1963
Dr. Robert E. Davis Ph.D.	Senior VP & Chief Scientific Officer	594,96k	N/A	1951
Mr. Juan Fernando Sanchez	Vice President of Corporate Communications & Investor Relations	273,25k	N/A	1971
Ms. Karen Patruno Sheehy Esq.	Senior VP & Chief Compliance Officer	N/A	N/A	1962
John P. Condon	Senior Vice President, General Counsel & Secretary	N/A	N/A	N/A
Dr. Michael Olchaskey	Senior VP & Head of Regulatory Affairs	N/A	N/A	N/A
Mr. John A. Bardi	Senior VP of Market Access, Policy & Government Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Corporate Governance

Intra-Cellular Therapies, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 7. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 7, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.